Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Swedish Orphan Biovitrum AB (publ)
  6. News
  7. Press Releases
    SOBI   SE0000872095

SWEDISH ORPHAN BIOVITRUM AB (PUBL)

(SOBI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société SWEDISH ORPHAN BIOVITRUM AB (PUBL)
05/10Bulletin from Swedish Orphan Biovitrum (Sobi®)'s Annual General Meeting (AGM)
AQ
04/28Sobi publishes Q1 2022 report
AQ
04/20INVITATION : Sobi's Q1 2022 report
AQ
04/06Swedish Orphan Biovitrum AB - Annual and Sustainability Report 2021
AQ
04/06Swedish Orphan Biovitrum AB - Notice of Annual General Meeting in Swedish Orphan Biovit..
AQ
04/05Sobi publishes 2021 Annual and Sustainability Report
AQ
04/05Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
AQ
03/23Sobi to cease ReFacto manufacturing in the first quarter of 2024
AQ
03/18Gamifant approved in China for the treatment of primary haemophagocytic lymphohistiocyt..
AQ
03/09Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in haemophi..
AQ
02/25Gamifant (emapalumab) recommended for approval in China for treatment of primary haemop..
AQ
02/11Swedish Orphan Biovitrum - Sobi publishes Q4 and FY 2021 report
AQ
02/10Sobi publishes Q4 and FY 2021 report
AQ
02/03INVITATION : Sobi's Q4 and FY 2021 report
AQ
02/02Sobi to present new data at EAHAD 2022
AQ
2021Kineret® (anakinra) receives positive opinion from the CHMP for treatment of patients w..
AQ
2021Aspaveli® (pegcetacoplan) approved in EU as orphan drug for treatment of PNH
AQ
2021Aspaveli®/Empaveli™ (pegcetacoplan) demonstrated sustained normalisation of clini..
AQ
2021Sobi continues the R&D transformation - Anders Ullman appointed new Head of R&D
AQ
2021Statement by the Board of Directors in relation to the withdrawal of the public cash of..
AQ
2021Sobi and Selecta Biosciences announce completion of enrolment in DISSOLVE Phase 3 study..
AQ
2021Sobi to present new data at the ASH 2021 Annual Meeting
AQ
2021SWEDISH ORPHAN BIOVITRUM : Sobi publishes report for the third quarter 2021
AQ
2021SWEDISH ORPHAN BIOVITRUM : Sobi publishes report for the third quarter 2021
AQ
2021SWEDISH ORPHAN BIOVITRUM : Aspaveli® (pegcetacoplan) receives positive CHMP opinion for tr..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Sobi announces preliminary headline numbers for the third quart..
AQ
2021SWEDISH ORPHAN BIOVITRUM : New number of shares and votes in Swedish Orphan Biovitrum AB (..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Nature Medicine publishes positive phase 3 anakinra study resul..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Nature Medicine publishes phase 3 anakinra study results in pat..
AQ
2021INVESTOR : supports Agnafit Bidco's bid for Sobi
AQ
2021SWEDISH ORPHAN BIOVITRUM : Statement by the Board of Directors of Swedish Orphan Biovitrum..
AQ
2021OASMIA PHARMACEUTICAL : strengthens internal capabilities with the appointments of Head of..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Board of directors exercises authorisation for repurchase of sh..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Sobi publishes report for the second quarter 2021
AQ
2021SWEDISH ORPHAN BIOVITRUM : The Board of directors exercises authorisation for repurchase o..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Invitation - Presentation of Sobi's Q2 2021 results
AQ
2021SWEDISH ORPHAN BIOVITRUM : Sobi to present data at the ISTH 2021 within rare haematology d..
AQ
2021SOBI AT EHA VIRTUAL CONGRESS 2021 : focus on results in PNH and treatment for ITP
AQ
2021SWEDISH ORPHAN BIOVITRUM : Positive top-line results from the phase 3 PRINCE study of pegc..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Early use of anakinra reduces risk of mortality for patients wi..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Bulletin from Swedish Orphan Biovitrum's ("Sobi") Annual Genera..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Sobi publishes report for the first quarter 2021
AQ
2021SOBI AND HELLENIC INSTITUTE FOR THE : anakinra improved overall clinical outcomes by 64% ..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Invitation - Presentation of Sobi's Q1 2021 results
AQ
2021SWEDISH ORPHAN BIOVITRUM : First patient dosed in phase 3 XTEND-Kids study with efanesocto..
AQ
2021IRLAB's nomination committee proposes Martin Nicklasson as new board member and provide..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Sobi™ publishes 2020 Annual and Sustainability Report
AQ
2021SWEDISH ORPHAN BIOVITRUM : Notice of Annual General Meeting in Swedish Orphan Biovitrum AB..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Evaluation of haemophilia A treatment options shows favourable ..
AQ
2021APELLIS PHARMACEUTICALS : Swedish Orphan Biovitrum AB - The NEJM publishes phase 3 PEGASUS..
AQ
2021SWEDISH ORPHAN BIOVITRUM : The NEJM publishes phase 3 PEGASUS study results comparing pegc..
AQ
2021SWEDISH ORPHAN BIOVITRUM : First patient dosed in phase 3 study with avatrombopag for trea..
AQ
2021RARE DISEASE DAY 2021 : Pandemic illuminates every day social obstacles of living with a r..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Sobi publishes report for the fourth quarter and full-year 2020
AQ
2021SWEDISH ORPHAN BIOVITRUM : Kineret approved in Russia for the treatment of CAPS
AQ
2021SWEDISH ORPHAN BIOVITRUM : Kineret® (anakinra) approved in Russia for the treatment of CAP..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Invitation - Presentation of Sobi's Q4 and FY 2020 results
AQ
2021SWEDISH ORPHAN BIOVITRUM : Sobi showcases commitment to haemophilia community at EAHAD 202..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Favourable results for Elocta® when evaluating treatment option..
AQ
2021SWEDISH ORPHAN BIOVITRUM : Doptelet® (avatrombopag) approved in the EU for treatment of IT..
AQ
2020FDA Approves KINERET® (anakinra) for the Treatment of Deficiency of IL-1 Receptor Antag..
GL
2020SWEDISH ORPHAN BIOVITRUM : Sobi appoints new Head of North America ahead of launch phase
AQ
2020SWEDISH ORPHAN BIOVITRUM : Doptelet receives positive opinion from CHMP for treatment of I..
AQ
2020SWEDISH ORPHAN BIOVITRUM : Realising opportunities for future growth and financial update,..
AQ
2020SWEDISH ORPHAN BIOVITRUM : Emapalumab submission in China for primary HLH
AQ
2020SWEDISH ORPHAN BIOVITRUM : Doptelet® (avatrombopag) receives positive opinion from CHMP fo..
AQ
2020SWEDISH ORPHAN BIOVITRUM : Sobi and Apellis report positive top-line results at 48 weeks f..
AQ
2020SWEDISH ORPHAN BIOVITRUM : Emapalumab submission in China for primary HLH
AQ
2020REALISING OPPORTUNITIES FOR FUTURE G : Sobi Capital Markets Day 2020
AQ
2020SWEDISH ORPHAN BIOVITRUM : Agenda, Sobi Capital Markets Day 2020
AQ
2020AGENDA : Sobi Capital Markets Day 2020
AQ
2020SWEDISH ORPHAN BIOVITRUM : Sobi and Apellis announce first patient dosed in potentially re..
AQ
2020SWEDISH ORPHAN BIOVITRUM : CHMP has adopted a negative opinion for emapalumab in Europe fo..
AQ
2020SWEDISH ORPHAN BIOVITRUM : The CHMP has adopted a negative opinion for emapalumab in Europ..
AQ
2020SWEDISH ORPHAN BIOVITRUM : Strong Sobi presence at American Society of Hematology 2020 Ann..
AQ
1  2  3  4Next
Stock Pick
 SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Consistent Growth, Surprisingly Affordable Valuation
Upcoming event on SWEDISH ORPHAN BIOVITRUM AB (PUBL)
07/19/22Interim 2022 Earnings Release
Upcoming sector events
07/26/22BIOGEN INC. : Interim 2022 Earnings Release (Projected)
08/16/22SAMSUNG BIOLOGICS CO.,LTD. : Interim 2022 Earnings Release (Projected)
08/17/22CSL LIMITED : FY 2022 Earnings Release
08/22/22WUXI BIOLOGICS (CAYMAN) INC. : Interim 2022 Earnings Release (Projected)
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Biopharmaceuticals